Search

Your search keyword '"Brooks, Stephen"' showing total 2,099 results
Start Over Author "Brooks, Stephen"

Refine your results

more »

more »

more »

more »

more »
2,099 results on '"Brooks, Stephen"'

2. Cover

Author

Brooks, Stephen and Olive, Andrea

Published
2018

4. Index

Author

Brooks, Stephen and Olive, Andrea

Published
2018

12. Preface

Author

Brooks, Stephen and Olive, Andrea

Published
2018

17. Thresholds for adding degraded tropical forest to the conservation estate

Author

Ewers, Robert M., Orme, C. David L., Pearse, William D., Zulkifli, Nursyamin, Yvon-Durocher, Genevieve, Yusah, Kalsum M., Yoh, Natalie, Yeo, Darren C. J., Wong, Anna, Williamson, Joseph, Wilkinson, Clare L., Wiederkehr, Fabienne, Webber, Bruce L., Wearn, Oliver R., Wai, Leona, Vollans, Maisie, Twining, Joshua P., Turner, Edgar C., Tobias, Joseph A., Thorley, Jack, Telford, Elizabeth M., Teh, Yit Arn, Tan, Heok Hui, Swinfield, Tom, Svátek, Martin, Struebig, Matthew, Stork, Nigel, Sleutel, Jani, Slade, Eleanor M., Sharp, Adam, Shabrani, Adi, Sethi, Sarab S., Seaman, Dave J. I., Sawang, Anati, Roxby, Gabrielle Briana, Rowcliffe, J. Marcus, Rossiter, Stephen J., Riutta, Terhi, Rahman, Homathevi, Qie, Lan, Psomas, Elizabeth, Prairie, Aaron, Poznansky, Frederica, Pillay, Rajeev, Picinali, Lorenzo, Pianzin, Annabel, Pfeifer, Marion, Parrett, Jonathan M., Noble, Ciar D., Nilus, Reuben, Mustaffa, Nazirah, Mullin, Katherine E., Mitchell, Simon, Mckinlay, Amelia R., Maunsell, Sarah, Matula, Radim, Massam, Michael, Martin, Stephanie, Malhi, Yadvinder, Majalap, Noreen, Maclean, Catherine S., Mackintosh, Emma, Luke, Sarah H., Lewis, Owen T., Layfield, Harry J., Lane-Shaw, Isolde, Kueh, Boon Hee, Kratina, Pavel, Konopik, Oliver, Kitching, Roger, Kinneen, Lois, Kemp, Victoria A., Jotan, Palasiah, Jones, Nick, Jebrail, Evyen W., Hroneš, Michal, Heon, Sui Peng, Hemprich-Bennett, David R., Haysom, Jessica K., Harianja, Martina F., Hardwick, Jane, Gregory, Nichar, Gray, Ryan, Gray, Ross E. J., Granville, Natasha, Gill, Richard, Fraser, Adam, Foster, William A., Folkard-Tapp, Hollie, Fletcher, Robert J., Fikri, Arman Hadi, Fayle, Tom M., Faruk, Aisyah, Eggleton, Paul, Edwards, David P., Drinkwater, Rosie, Dow, Rory A., Döbert, Timm F., Didham, Raphael K., Dickinson, Katharine J. M., Deere, Nicolas J., de Lorm, Tijmen, Dawood, Mahadimenakbar M., Davison, Charles W., Davies, Zoe G., Davies, Richard G., Dančák, Martin, Cusack, Jeremy, Clare, Elizabeth L., Chung, Arthur, Chey, Vun Khen, Chapman, Philip M., Cator, Lauren, Carpenter, Daniel, Carbone, Chris, Calloway, Kerry, Bush, Emma R., Burslem, David F. R. P., Brown, Keiron D., Brooks, Stephen J., Brasington, Ella, Brant, Hayley, Boyle, Michael J. W., Both, Sabine, Blackman, Joshua, Bishop, Tom R., Bicknell, Jake E., Bernard, Henry, Basrur, Saloni, Barclay, Maxwell V. L., Barclay, Holly, Atton, Georgina, Ancrenaz, Marc, Aldridge, David C., Daniel, Olivia Z., Reynolds, Glen, and Banks-Leite, Cristina

Published
2024
Full Text
View/download PDF

21. Higher-Order Corrections to Optimisers based on Newton's Method

Author

Brooks, Stephen

Subjects
Mathematics - Numerical Analysis
Abstract

The Newton, Gauss--Newton and Levenberg--Marquardt methods all use the first derivative of a vector function (the Jacobian) to minimise its sum of squares. When the Jacobian matrix is ill-conditioned, the function varies much faster in some directions than others and the space of possible improvement in sum of squares becomes a long narrow ellipsoid in the linear model. This means that even a small amount of nonlinearity in the problem parameters can cause a proposed point far down the long axis of the ellipsoid to fall outside of the actual curved valley of improved values, even though it is quite nearby. This paper presents a differential equation that `follows' these valleys, based on the technique of geodesic acceleration, which itself provides a 2$^\mathrm{nd}$ order improvement to the Levenberg--Marquardt iteration step. Higher derivatives of this equation are computed that allow $n^\mathrm{th}$ order improvements to the optimisation methods to be derived. These higher-order accelerated methods up to 4$^\mathrm{th}$ order are tested numerically and shown to provide substantial reduction of both number of steps and computation time.

Published
2023

24. Contents

Author

Brooks, Stephen

Published
2006

26. References

Author

Brooks, Stephen

Published
2006

33. Preface

Author

Brooks, Stephen

Published
2006

34. Index

Author

Brooks, Stephen

Published
2006

38. Regional impacts of warming on biodiversity and biomass in high latitude stream ecosystems across the Northern Hemisphere

Author

Jackson, Michelle C., Friberg, Nikolai, Moliner Cachazo, Luis, Clark, David R., Mutinova, Petra Thea, O’Gorman, Eoin J., Kordas, Rebecca L., Gallo, Bruno, Pichler, Doris E., Bespalaya, Yulia, Aksenova, Olga V., Milner, Alexander, Brooks, Stephen J., Dunn, Nicholas, Lee, K.W.K., Ólafsson, Jón S., Gíslason, Gísli M., Millan, Lucia, Bell, Thomas, Dumbrell, Alex J., and Woodward, Guy

Published
2024
Full Text
View/download PDF

40. Correspondence: Striking the Balance

Author

Art, Robert J, Brooks, Stephen G., Wohlforth, William Curti, Lieber, Keir A. (Keir Alexander), and Alexander, Gerard

Published
2006

48. Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19

Author

Wigerblad, Gustaf, Warner, Seth A, Ramos-Benitez, Marcos J, Kardava, Lela, Tian, Xin, Miao, Rui, Reger, Robert, Chakraborty, Mala, Wong, Susan, Kanthi, Yogendra, Suffredini, Anthony F, Dell’Orso, Stefania, Brooks, Stephen, King, Christopher, Shlobin, Oksana, Nathan, Steven D, Cohen, Jonathan, Moir, Susan, Childs, Richard W, Kaplan, Mariana J, Chertow, Daniel S, and Strich, Jeffrey R

Subjects
Biomedical and Clinical Sciences, Immunology, Clinical Research, Clinical Trials and Supportive Activities, Prevention, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Syk Kinase, COVID-19, Oxazines, HLA-DR Antigens, Homeostasis
Abstract

Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase 2 placebo-controlled randomized clinical trial and was associated with improvements in many secondary end points related to efficacy. Here, we used a multiomic approach to evaluate cellular and soluble immune mediator responses of patients enrolled in this trial. We demonstrated that SYK inhibition was associated with reduced neutrophil activation, increased circulation of mature neutrophils (CD10+CD33-), and decreased circulation of low-density granulocytes and polymorphonuclear myeloid-derived suppressor cells (HLA-DR-CD33+CD11b-). SYK inhibition was also associated with normalization of transcriptional activity in circulating monocytes relative to healthy controls, an increase in frequency of circulating nonclassical and HLA-DRhi classical monocyte populations, and restoration of interferon responses. Together, these data suggest that SYK inhibition may mitigate proinflammatory myeloid cellular and soluble mediator responses thought to contribute to immunopathogenesis of severe COVID-19.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results